Ionis' brain disorder drug shows promise in clinical trial
22/09/2025 12:06
Sept 22 (Reuters) - Ionis Pharmaceuticals IONS.O said on Monday its experimental brain disorder drug met the main goal in an early-to-late-stage study. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors